Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-PHIRE: AZD3427 in Heart Failure and Pulmonary Hypertension Due to Left Heart Disease
NCT05737940Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 2 trial of AZD3427 in heart failure (HF), pulmonary hypertension (PH), sponsored by AstraZeneca. Started Apr 2023; status: completed.
02
Drugs
AZD3427
03
Conditions
heart failure (HF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT05737940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737940.